MX374705B - Composiciones que comprenden anakinra. - Google Patents

Composiciones que comprenden anakinra.

Info

Publication number
MX374705B
MX374705B MX2017013879A MX2017013879A MX374705B MX 374705 B MX374705 B MX 374705B MX 2017013879 A MX2017013879 A MX 2017013879A MX 2017013879 A MX2017013879 A MX 2017013879A MX 374705 B MX374705 B MX 374705B
Authority
MX
Mexico
Prior art keywords
compositions
anakinra
include anakinra
optionally
relates
Prior art date
Application number
MX2017013879A
Other languages
English (en)
Other versions
MX2017013879A (es
Inventor
Barry D Moore
Ebba Florin-Robertsson
Jonas Fransson
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MX2017013879A publication Critical patent/MX2017013879A/es
Publication of MX374705B publication Critical patent/MX374705B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden anakinra, regulador de pH, y opcionalmente al menos un osmolito y opcionalmente otros excipientes; además, la presente invención se refiere al uso de dichas composiciones para el tratamiento de, por ejemplo, trastornos oftálmicos.
MX2017013879A 2015-04-28 2016-04-27 Composiciones que comprenden anakinra. MX374705B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15165421 2015-04-28
PCT/EP2016/059398 WO2016174082A1 (en) 2015-04-28 2016-04-27 Compositions comprising anakinra

Publications (2)

Publication Number Publication Date
MX2017013879A MX2017013879A (es) 2018-08-01
MX374705B true MX374705B (es) 2025-03-06

Family

ID=53015628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013879A MX374705B (es) 2015-04-28 2016-04-27 Composiciones que comprenden anakinra.

Country Status (15)

Country Link
US (1) US11324807B2 (es)
EP (1) EP3288536B1 (es)
JP (1) JP6769994B2 (es)
KR (1) KR102582560B1 (es)
CN (1) CN107645956B (es)
AU (1) AU2016256217B2 (es)
CA (1) CA2983783A1 (es)
DK (1) DK3288536T3 (es)
ES (1) ES2744605T3 (es)
IL (1) IL255275B (es)
MX (1) MX374705B (es)
RU (1) RU2728795C2 (es)
SG (1) SG11201708698XA (es)
WO (1) WO2016174082A1 (es)
ZA (1) ZA201707872B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
SG10201907137RA (en) * 2019-08-02 2021-03-30 Singapore Health Serv Pte Ltd Use of an osmolyte in manufacture of a medicament for treatment of ocular disorders
WO2022172284A1 (en) * 2021-02-11 2022-08-18 Gennova Biopharmaceuticals Ltd. Purification of a therapeutic protein
DE102021212692A1 (de) 2021-11-11 2023-05-11 Ursapharm Arzneimittel Gmbh Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion so-wie emulgierende zusammensetzung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
DE69233069T2 (de) * 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
PT1729810T (pt) 2004-04-02 2018-11-22 Swedish Orphan Biovitrum Ab Publ Métodos de redução da agregação de il-ira
US7695718B2 (en) * 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
CN101998965B (zh) * 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
WO2009064838A1 (en) * 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
HRP20160928T1 (hr) * 2011-02-11 2016-10-07 Swedish Orphan Biovitrum Ab (Publ) Farmaceutske kompozicije koje sadrže anakinra bez citrata
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
PL2968468T3 (pl) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Preparaty chimerycznej cytokiny do dostarczania do oka

Also Published As

Publication number Publication date
KR20170142185A (ko) 2017-12-27
IL255275A0 (en) 2017-12-31
RU2728795C2 (ru) 2020-07-31
CN107645956A (zh) 2018-01-30
US20180110836A1 (en) 2018-04-26
EP3288536A1 (en) 2018-03-07
JP2018514541A (ja) 2018-06-07
US11324807B2 (en) 2022-05-10
RU2017140495A3 (es) 2019-09-13
AU2016256217B2 (en) 2020-04-16
KR102582560B1 (ko) 2023-09-26
DK3288536T3 (da) 2019-09-23
EP3288536B1 (en) 2019-06-26
WO2016174082A1 (en) 2016-11-03
CA2983783A1 (en) 2016-11-03
MX2017013879A (es) 2018-08-01
BR112017022942A2 (pt) 2018-07-17
ES2744605T3 (es) 2020-02-25
CN107645956B (zh) 2021-07-20
RU2017140495A (ru) 2019-05-28
NZ737410A (en) 2024-05-31
IL255275B (en) 2020-06-30
ZA201707872B (en) 2020-01-29
AU2016256217A1 (en) 2017-12-07
SG11201708698XA (en) 2017-11-29
JP6769994B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
BR112018004620A2 (pt) moduladores da expressão de kras
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017001046A1 (es) Inhibidoes del bromodominio
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017027721A2 (pt) formulação de alta concentração
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2020001885A (es) Formulaciones de daptomicina.
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX374705B (es) Composiciones que comprenden anakinra.
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica

Legal Events

Date Code Title Description
FG Grant or registration